Rueb Yuliya received 2,925 Tyra Biosciences shares at $9.13 each, lifting the reported holding to 11,258 shares. The award matters to investors because it changes the disclosed ownership position and represents about 26.0% of the resulting holding, with the transaction classified under code A.
Key Highlights
- Rueb Yuliya’s reported Tyra Biosciences holding rose to 11,258 shares after the award.
- The transaction covered 2,925 shares priced at $9.13 per share.
- The award represented about 26.0% of Yuliya’s resulting share holding.
Rueb Yuliya received 2,925 shares of Tyra Biosciences, Inc. (NASDAQ: TYRA) at $9.13 per share on 15 September 2026. The award left Yuliya with 11,258 Tyra Biosciences shares, while the transaction represented about 26.0% of the resulting holding.
Award Adds to Yuliya’s Reported Position
The transaction date was 15 September 2026. Yuliya’s resulting ownership was 11,258 shares. The 2,925-share award accounted for about 26.0% of that resulting position. The reported ownership figure covers the holding after the award. Rueb Yuliya is identified in the source as Vice President, Finance (PAO) of Tyra Biosciences, Inc.
FAQs
Q: How many Tyra Biosciences shares did Rueb Yuliya receive?
A: Rueb Yuliya received 2,925 Tyra Biosciences shares in the award. The transaction was recorded at $9.13 per share on 15 September 2026.
Q: What was Rueb Yuliya’s resulting Tyra Biosciences shareholding?
A: Yuliya’s reported holding after the transaction was 11,258 Tyra Biosciences shares. The award represented about 26.0% of that resulting position.
Q: What does transaction code A mean in this Tyra Biosciences award?
A: Transaction code A denotes an award or grant. In this case, it covered 2,925 Tyra Biosciences shares awarded to Rueb Yuliya.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.